<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;utm_source=Chrome&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;ff=20240402160831&amp;utm_campaign=pubmed-2&amp;v=2.18.0.post9+e462414
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;utm_source=Chrome&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;ff=20240402160831&amp;utm_campaign=pubmed-2&amp;v=2.18.0.post9+e462414" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Tue, 02 Apr 2024 20:08:31 +0000</lastbuilddate>
<pubDate>Tue, 02 Apr 2024 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>Endothelial PTP1B Deletion Promotes VWF Exocytosis and Venous Thromboinflammation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38563147/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240402160831&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Our findings show that endothelial PTP1B deletion promotes venous thromboinflammation by enhancing SNAP23 phosphorylation, endothelial VWF exocytosis, and neutrophil recruitment.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Apr 2. doi: 10.1161/CIRCRESAHA.124.324214. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Endothelial activation promotes the release of procoagulant extracellular vesicles and inflammatory mediators from specialized storage granules. Endothelial membrane exocytosis is controlled by phosphorylation. We hypothesized that the absence of PTP1B (protein tyrosine phosphatase 1B) in endothelial cells promotes venous thromboinflammation by triggering endothelial membrane fusion and exocytosis.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Mice with inducible endothelial deletion of PTP1B (End.PTP1B-KO) underwent inferior vena cava ligation to induce stenosis and venous thrombosis. Primary endothelial cells from transgenic mice and human umbilical vein endothelial cells were used for mechanistic studies.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Vascular ultrasound and histology showed significantly larger venous thrombi containing higher numbers of Ly6G (lymphocyte antigen 6 family member G)-positive neutrophils in mice with endothelial PTP1B deletion, and intravital microscopy confirmed the more pronounced neutrophil recruitment following inferior vena cava ligation. RT<sup>2</sup> PCR profiler array and immunocytochemistry analysis revealed increased endothelial activation and adhesion molecule expression in primary End.PTP1B-KO endothelial cells, including CD62P (P-selectin) and VWF (von Willebrand factor). Pretreatment with the NF-κB (nuclear factor kappa B) kinase inhibitor BAY11-7082, antibodies neutralizing CD162 (P-selectin glycoprotein ligand-1) or VWF, or arginylglycylaspartic acid integrin-blocking peptides abolished the neutrophil adhesion to End.PTP1B-KO endothelial cells in vitro. Circulating levels of annexin V<sup>+</sup> procoagulant endothelial CD62E<sup>+</sup> (E-selectin) and neutrophil (Ly6G<sup>+</sup>) extracellular vesicles were also elevated in End.PTP1B-KO mice after inferior vena cava ligation. Higher plasma MPO (myeloperoxidase) and Cit-H3 (citrullinated histone-3) levels and neutrophil elastase activity indicated neutrophil activation and extracellular trap formation. Infusion of End.PTP1B-KO extracellular vesicles into C57BL/6J wild-type mice most prominently enhanced the recruitment of endogenous neutrophils, and this response was blunted in VWF-deficient mice or by VWF-blocking antibodies. Reduced PTP1B binding and tyrosine dephosphorylation of SNAP23 (synaptosome-associated protein 23) resulting in increased VWF exocytosis and neutrophil adhesion were identified as mechanisms, all of which could be restored by NF-κB kinase inhibition using BAY11-7082.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Our findings show that endothelial PTP1B deletion promotes venous thromboinflammation by enhancing SNAP23 phosphorylation, endothelial VWF exocytosis, and neutrophil recruitment.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38563147/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240402160831&v=2.18.0.post9+e462414">38563147</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.124.324214>10.1161/CIRCRESAHA.124.324214</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38563147</guid>
<pubDate>Tue, 02 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Konstantinos Zifkos</dc:creator>
<dc:creator>Magdalena L Bochenek</dc:creator>
<dc:creator>Rajinikanth Gogiraju</dc:creator>
<dc:creator>Stephane Robert</dc:creator>
<dc:creator>Denise Pedrosa</dc:creator>
<dc:creator>Klytaimnistra Kiouptsi</dc:creator>
<dc:creator>Kateryna Moiko</dc:creator>
<dc:creator>Mathias Wagner</dc:creator>
<dc:creator>Felix Mahfoud</dc:creator>
<dc:creator>Philippe Poncelet</dc:creator>
<dc:creator>Thomas Münzel</dc:creator>
<dc:creator>Wolfram Ruf</dc:creator>
<dc:creator>Christoph Reinhardt</dc:creator>
<dc:creator>Laurence Panicot-Dubois</dc:creator>
<dc:creator>Christophe Dubois</dc:creator>
<dc:creator>Katrin Schäfer</dc:creator>
<dc:date>2024-04-02</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Endothelial PTP1B Deletion Promotes VWF Exocytosis and Venous Thromboinflammation</dc:title>
<dc:identifier>pmid:38563147</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.124.324214</dc:identifier>
</item>
<item>
<title>Association Between Chest Compression Pause Duration and Survival After Pediatric In-Hospital Cardiac Arrest</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38563137/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240402160831&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Each 5-second increment in longest CC pause duration during pediatric in-hospital cardiac arrest was associated with lower chance of survival with favorable neurological outcome, survival to hospital discharge, and return of spontaneous circulation. Any CC pause >;10 seconds or >;20 seconds and number of pauses >;10 seconds and >;20 seconds were significantly associated with lower adjusted probability of return of spontaneous circulation, but not survival or neurological outcomes.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Apr 2. doi: 10.1161/CIRCULATIONAHA.123.066882. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: The association between chest compression (CC) pause duration and pediatric in-hospital cardiac arrest survival outcomes is unknown. The American Heart Association has recommended minimizing pauses in CC in children to &lt;10 seconds, without supportive evidence. We hypothesized that longer maximum CC pause durations are associated with worse survival and neurologicalal outcomes.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: In this cohort study of index pediatric in-hospital cardiac arrests reported in pediRES-Q (Quality of Pediatric Resuscitation in a Multicenter Collaborative) from July of 2015 through December of 2021, we analyzed the association in 5-second increments of the longest CC pause duration for each event with survival and favorable neurological outcome (Pediatric Cerebral Performance Category ≤3 or no change from baseline). Secondary exposures included having any pause >;10 seconds or >;20 seconds and number of pauses >;10 seconds and >;20 seconds per 2 minutes.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: We identified 562 index in-hospital cardiac arrests (median [Q1, Q3] age 2.9 years [0.6, 10.0], 43% female, 13% shockable rhythm). Median length of the longest CC pause for each event was 29.8 seconds (11.5, 63.1). After adjustment for confounders, each 5-second increment in the longest CC pause duration was associated with a 3% lower relative risk of survival with favorable neurological outcome (absolute risk reduction, 0.97 [95% CI, 0.95-0.99]; <i>P</i>=0.02). Longest CC pause duration was also associated with survival to hospital discharge (absolute risk reduction, 0.98 [95% CI, 0.96-0.99]; <i>P</i>=0.01) and return of spontaneous circulation (absolute risk reduction, 0.93 [95% CI, 0.91-0.94]; <i>P</i>&lt;0.001). Secondary outcomes of any pause >;10 seconds or >;20 seconds and number of CC pauses >;10 seconds and >;20 seconds were each significantly associated with lower absolute risk reduction of return of spontaneous circulation, but not survival or neurological outcomes.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Each 5-second increment in longest CC pause duration during pediatric in-hospital cardiac arrest was associated with lower chance of survival with favorable neurological outcome, survival to hospital discharge, and return of spontaneous circulation. Any CC pause >;10 seconds or >;20 seconds and number of pauses >;10 seconds and >;20 seconds were significantly associated with lower adjusted probability of return of spontaneous circulation, but not survival or neurological outcomes.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38563137/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240402160831&v=2.18.0.post9+e462414">38563137</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.066882>10.1161/CIRCULATIONAHA.123.066882</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38563137</guid>
<pubDate>Tue, 02 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Kasper G Lauridsen</dc:creator>
<dc:creator>Ryan W Morgan</dc:creator>
<dc:creator>Robert A Berg</dc:creator>
<dc:creator>Dana E Niles</dc:creator>
<dc:creator>Monica E Kleinman</dc:creator>
<dc:creator>Xuemei Zhang</dc:creator>
<dc:creator>Heather Griffis</dc:creator>
<dc:creator>Jimena Del Castillo</dc:creator>
<dc:creator>Sophie Skellett</dc:creator>
<dc:creator>Javier J Lasa</dc:creator>
<dc:creator>Tia T Raymond</dc:creator>
<dc:creator>Robert M Sutton</dc:creator>
<dc:creator>Vinay M Nadkarni</dc:creator>
<dc:creator>pediRES-Q Investigators</dc:creator>
<dc:date>2024-04-02</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Association Between Chest Compression Pause Duration and Survival After Pediatric In-Hospital Cardiac Arrest</dc:title>
<dc:identifier>pmid:38563137</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.066882</dc:identifier>
</item>
<item>
<title>Age-Dependent RGS5 Loss in Pericytes Induces Cardiac Dysfunction and Fibrosis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38563133/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240402160831&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Our results have identified RGS5 as a crucial regulator of pericyte function during cardiac aging. The deletion of RGS5 causes cardiac dysfunction and induces myocardial fibrosis, one of the hallmarks of cardiac aging.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Apr 2. doi: 10.1161/CIRCRESAHA.123.324183. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Pericytes are capillary-associated mural cells involved in the maintenance and stability of the vascular network. Although aging is one of the main risk factors for cardiovascular disease, the consequences of aging on cardiac pericytes are unknown.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: In this study, we have combined single-nucleus RNA sequencing and histological analysis to determine the effects of aging on cardiac pericytes. Furthermore, we have conducted in vivo and in vitro analysis of RGS5 (regulator of G-protein signaling 5) loss of function and finally have performed pericytes-fibroblasts coculture studies to understand the effect of RGS5 deletion in pericytes on the neighboring fibroblasts.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Aging reduced the pericyte area and capillary coverage in the murine heart. Single-nucleus RNA sequencing analysis further revealed that the expression of <i>Rgs5</i> was reduced in cardiac pericytes from aged mice. In vivo and in vitro studies showed that the deletion of RGS5 impaired cardiac function, induced fibrosis, and morphological changes in pericytes characterized by a profibrotic gene expression signature and the expression of different ECM (extracellular matrix) components and growth factors, for example, <i>TGFB2</i> and <i>PDGFB</i>. Indeed, culturing fibroblasts with the supernatant of RGS5-deficient pericytes induced their activation as evidenced by the increased expression of αSMA (alpha smooth muscle actin) in a TGFβ (transforming growth factor beta)2-dependent mechanism.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Our results have identified RGS5 as a crucial regulator of pericyte function during cardiac aging. The deletion of RGS5 causes cardiac dysfunction and induces myocardial fibrosis, one of the hallmarks of cardiac aging.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38563133/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240402160831&v=2.18.0.post9+e462414">38563133</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.123.324183>10.1161/CIRCRESAHA.123.324183</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38563133</guid>
<pubDate>Tue, 02 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Anita Tamiato</dc:creator>
<dc:creator>Lukas S Tombor</dc:creator>
<dc:creator>Ariane Fischer</dc:creator>
<dc:creator>Marion Muhly-Reinholz</dc:creator>
<dc:creator>Leah Rebecca Vanicek</dc:creator>
<dc:creator>Büşra Nur Toğru</dc:creator>
<dc:creator>Jessica Neitz</dc:creator>
<dc:creator>Simone Franziska Glaser</dc:creator>
<dc:creator>Maximilian Merten</dc:creator>
<dc:creator>David Rodriguez Morales</dc:creator>
<dc:creator>Jeonghyeon Kwon</dc:creator>
<dc:creator>Stephan Klatt</dc:creator>
<dc:creator>Bianca Schumacher</dc:creator>
<dc:creator>Stefan Günther</dc:creator>
<dc:creator>Wesley T Abplanalp</dc:creator>
<dc:creator>David John</dc:creator>
<dc:creator>Ingrid Fleming</dc:creator>
<dc:creator>Nina Wettschureck</dc:creator>
<dc:creator>Stefanie Dimmeler</dc:creator>
<dc:creator>Guillermo Luxán</dc:creator>
<dc:date>2024-04-02</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Age-Dependent RGS5 Loss in Pericytes Induces Cardiac Dysfunction and Fibrosis</dc:title>
<dc:identifier>pmid:38563133</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.123.324183</dc:identifier>
</item>
<item>
<title>JACC Focus Seminar on Mechanical Complications of Acute Myocardial Infarction</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38561163/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240402160831&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Mar 30:S0735-1097(24)06820-7. doi: 10.1016/j.jacc.2024.03.414. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38561163/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240402160831&v=2.18.0.post9+e462414">38561163</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.03.414>10.1016/j.jacc.2024.03.414</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38561163</guid>
<pubDate>Mon, 01 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Pedro R Moreno</dc:creator>
<dc:creator>Valentin Fuster</dc:creator>
<dc:date>2024-04-01</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>JACC Focus Seminar on Mechanical Complications of Acute Myocardial Infarction</dc:title>
<dc:identifier>pmid:38561163</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.03.414</dc:identifier>
</item>
<item>
<title>Focus on device innovation in interventional cardiology and on trials in cardiovascular prevention</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38558243/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240402160831&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Apr 1;45(13):1089-1093. doi: 10.1093/eurheartj/ehae180.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38558243/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240402160831&v=2.18.0.post9+e462414">38558243</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae180>10.1093/eurheartj/ehae180</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38558243</guid>
<pubDate>Mon, 01 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Filippo Crea</dc:creator>
<dc:date>2024-04-01</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Focus on device innovation in interventional cardiology and on trials in cardiovascular prevention</dc:title>
<dc:identifier>pmid:38558243</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae180</dc:identifier>
</item>
<item>
<title>Fifty years of percutaneous transluminal angioplasty</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38558170/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240402160831&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Apr 1:ehae145. doi: 10.1093/eurheartj/ehae145. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38558170/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240402160831&v=2.18.0.post9+e462414">38558170</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae145>10.1093/eurheartj/ehae145</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38558170</guid>
<pubDate>Mon, 01 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Marco Roffi</dc:creator>
<dc:creator>Bernhard Meier</dc:creator>
<dc:creator>Augusto Gallino</dc:creator>
<dc:date>2024-04-01</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Fifty years of percutaneous transluminal angioplasty</dc:title>
<dc:identifier>pmid:38558170</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae145</dc:identifier>
</item>
<item>
<title>Weekly journal scan: the KCa2 potassium channel as a promising target for the pharmacologic cardioversion of atrial fibrillation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38558097/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240402160831&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Apr 1:ehae138. doi: 10.1093/eurheartj/ehae138. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38558097/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240402160831&v=2.18.0.post9+e462414">38558097</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae138>10.1093/eurheartj/ehae138</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38558097</guid>
<pubDate>Mon, 01 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Giovanna Liuzzo</dc:creator>
<dc:creator>Daniela Pedicino</dc:creator>
<dc:date>2024-04-01</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Weekly journal scan: the KCa2 potassium channel as a promising target for the pharmacologic cardioversion of atrial fibrillation</dc:title>
<dc:identifier>pmid:38558097</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae138</dc:identifier>
</item>
<item>
<title>Intravascular Imaging for Guiding Percutaneous Coronary Intervention: What Does the Totality of Data Suggest, and Where Should We Go?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38557127/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240402160831&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Apr 2;149(14):1087-1089. doi: 10.1161/CIRCULATIONAHA.123.067916. Epub 2024 Apr 1.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38557127/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240402160831&v=2.18.0.post9+e462414">38557127</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.067916>10.1161/CIRCULATIONAHA.123.067916</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38557127</guid>
<pubDate>Mon, 01 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Akiko Maehara</dc:creator>
<dc:creator>Yoichiro Sugizaki</dc:creator>
<dc:date>2024-04-01</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Intravascular Imaging for Guiding Percutaneous Coronary Intervention: What Does the Totality of Data Suggest, and Where Should We Go?</dc:title>
<dc:identifier>pmid:38557127</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.067916</dc:identifier>
</item>
<item>
<title>Correction to: INO80-Dependent Remodeling of Transcriptional Regulatory Network Underlies the Progression of Heart Failure</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38557126/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240402160831&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Apr 2;149(14):e1066. doi: 10.1161/CIR.0000000000001235. Epub 2024 Apr 1.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38557126/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240402160831&v=2.18.0.post9+e462414">38557126</a> | DOI:<a href=https://doi.org/10.1161/CIR.0000000000001235>10.1161/CIR.0000000000001235</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38557126</guid>
<pubDate>Mon, 01 Apr 2024 06:00:00 -0400</pubDate>
<dc:date>2024-04-01</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Correction to: INO80-Dependent Remodeling of Transcriptional Regulatory Network Underlies the Progression of Heart Failure</dc:title>
<dc:identifier>pmid:38557126</dc:identifier>
<dc:identifier>doi:10.1161/CIR.0000000000001235</dc:identifier>
</item>
<item>
<title>Distinct Plasma Extracellular Vesicle Transcriptomes in Acute Decompensated Heart Failure Subtypes: A Liquid Biopsy Approach</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38557125/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240402160831&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Apr 2;149(14):1147-1149. doi: 10.1161/CIRCULATIONAHA.123.065513. Epub 2024 Apr 1.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38557125/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240402160831&v=2.18.0.post9+e462414">38557125</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065513>10.1161/CIRCULATIONAHA.123.065513</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38557125</guid>
<pubDate>Mon, 01 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Priyanka Gokulnath</dc:creator>
<dc:creator>Michail Spanos</dc:creator>
<dc:creator>H Immo Lehmann</dc:creator>
<dc:creator>Quanhu Sheng</dc:creator>
<dc:creator>Rodosthenis Rodosthenous</dc:creator>
<dc:creator>Mark Chaffin</dc:creator>
<dc:creator>Dimitrios Varrias</dc:creator>
<dc:creator>Emeli Chatterjee</dc:creator>
<dc:creator>Elizabeth Hutchins</dc:creator>
<dc:creator>Guoping Li</dc:creator>
<dc:creator>George Daaboul</dc:creator>
<dc:creator>Farhan Rana</dc:creator>
<dc:creator>Ashley Mingyi Wang</dc:creator>
<dc:creator>Kendall Van Keuren-Jensen</dc:creator>
<dc:creator>Patrick T Ellinor</dc:creator>
<dc:creator>Ravi Shah</dc:creator>
<dc:creator>Saumya Das</dc:creator>
<dc:date>2024-04-01</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Distinct Plasma Extracellular Vesicle Transcriptomes in Acute Decompensated Heart Failure Subtypes: A Liquid Biopsy Approach</dc:title>
<dc:identifier>pmid:38557125</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.065513</dc:identifier>
</item>
<item>
<title>Prevention of Sudden Cardiac Death: Beyond Automated External Defibrillators and Implantable Cardioverter Defibrillators</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38557124/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240402160831&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Apr 2;149(14):1059-1061. doi: 10.1161/CIRCULATIONAHA.123.066984. Epub 2024 Apr 1.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38557124/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240402160831&v=2.18.0.post9+e462414">38557124</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.066984>10.1161/CIRCULATIONAHA.123.066984</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38557124</guid>
<pubDate>Mon, 01 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Sumeet S Chugh</dc:creator>
<dc:date>2024-04-01</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Prevention of Sudden Cardiac Death: Beyond Automated External Defibrillators and Implantable Cardioverter Defibrillators</dc:title>
<dc:identifier>pmid:38557124</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.066984</dc:identifier>
</item>
<item>
<title>Preemptive Versus Urgent Heart Failure Hospitalization as a Surrogate for Mortality Risk in Heart Failure</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38557123/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240402160831&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Apr 2;149(14):1062-1064. doi: 10.1161/CIRCULATIONAHA.123.068066. Epub 2024 Apr 1.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38557123/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240402160831&v=2.18.0.post9+e462414">38557123</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.068066>10.1161/CIRCULATIONAHA.123.068066</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38557123</guid>
<pubDate>Mon, 01 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Chris J Kapelios</dc:creator>
<dc:creator>Lars H Lund</dc:creator>
<dc:date>2024-04-01</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Preemptive Versus Urgent Heart Failure Hospitalization as a Surrogate for Mortality Risk in Heart Failure</dc:title>
<dc:identifier>pmid:38557123</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.068066</dc:identifier>
</item>
<item>
<title>Highlights From the &lt;em>;Circulation&lt;/em>; Family of Journals</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38557122/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240402160831&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Apr 2;149(14):1139-1144. doi: 10.1161/CIRCULATIONAHA.124.069400. Epub 2024 Apr 1.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38557122/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240402160831&v=2.18.0.post9+e462414">38557122</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.069400>10.1161/CIRCULATIONAHA.124.069400</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38557122</guid>
<pubDate>Mon, 01 Apr 2024 06:00:00 -0400</pubDate>
<dc:date>2024-04-01</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Highlights From the &lt;em>;Circulation&lt;/em>; Family of Journals</dc:title>
<dc:identifier>pmid:38557122</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.069400</dc:identifier>
</item>
<item>
<title>CD151 Maintains Endolysosomal Protein Quality to Inhibit Vascular Inflammation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38557119/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240402160831&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Distinct from its canonical function in strengthening cell adhesion at cell surface, CD151 maintains endolysosome function by sustaining VCP/p97-mediated protein unfolding and turnover. By supporting protein quality control and protein degradation, CD151 prevents proteins from (1) buildup in endolysosomes and (2) discharge through exosomes, to limit vascular inflammation. Also, our study conceptualizes that balance between degradation and discharge of proteins in endothelial cells...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Apr 1. doi: 10.1161/CIRCRESAHA.123.323190. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Tetraspanin CD151 is highly expressed in endothelia and reinforces cell adhesion, but its role in vascular inflammation remains largely unknown.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: In vitro molecular and cellular biological analyses on genetically modified endothelial cells, in vivo vascular biological analyses on genetically engineered mouse models, and in silico systems biology and bioinformatics analyses on CD151-related events.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Endothelial ablation of <i>Cd151</i> leads to pulmonary and cardiac inflammation, severe sepsis, and perilous COVID-19, and endothelial CD151 becomes downregulated in inflammation. Mechanistically, CD151 restrains endothelial release of proinflammatory molecules for less leukocyte infiltration. At the subcellular level, CD151 determines the integrity of multivesicular bodies/lysosomes and confines the production of exosomes that carry cytokines such as ANGPT2 (angiopoietin-2) and proteases such as cathepsin-D. At the molecular level, CD151 docks VCP (valosin-containing protein)/p97, which controls protein quality via mediating deubiquitination for proteolytic degradation, onto endolysosomes to facilitate VCP/p97 function. At the endolysosome membrane, CD151 links VCP/p97 to (1) IFITM3, which regulates multivesicular body functions, to restrain IFITM3-mediated exosomal sorting, and (2) V-ATPase, which dictates endolysosome pH, to support functional assembly of V-ATPase.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Distinct from its canonical function in strengthening cell adhesion at cell surface, CD151 maintains endolysosome function by sustaining VCP/p97-mediated protein unfolding and turnover. By supporting protein quality control and protein degradation, CD151 prevents proteins from (1) buildup in endolysosomes and (2) discharge through exosomes, to limit vascular inflammation. Also, our study conceptualizes that balance between degradation and discharge of proteins in endothelial cells determines vascular information. Thus, the IFITM3/V-ATPase-tetraspanin-VCP/p97 complexes on endolysosome, as a protein quality control and inflammation-inhibitory machinery, could be beneficial for therapeutic intervention against vascular inflammation.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38557119/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240402160831&v=2.18.0.post9+e462414">38557119</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.123.323190>10.1161/CIRCRESAHA.123.323190</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38557119</guid>
<pubDate>Mon, 01 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Junxiong Chen</dc:creator>
<dc:creator>Yingjun Ding</dc:creator>
<dc:creator>Chao Jiang</dc:creator>
<dc:creator>Rongmei Qu</dc:creator>
<dc:creator>Jonathan D Wren</dc:creator>
<dc:creator>Constantin Georgescu</dc:creator>
<dc:creator>Xuejun Wang</dc:creator>
<dc:creator>Darlene N Reuter</dc:creator>
<dc:creator>Beibei Liu</dc:creator>
<dc:creator>Cory B Giles</dc:creator>
<dc:creator>Christoph H Mayr</dc:creator>
<dc:creator>Herbert B Schiller</dc:creator>
<dc:creator>Jingxing Dai</dc:creator>
<dc:creator>Christopher S Stipp</dc:creator>
<dc:creator>Bharathiraja Subramaniyan</dc:creator>
<dc:creator>Jie Wang</dc:creator>
<dc:creator>Houjuan Zuo</dc:creator>
<dc:creator>Chao Huang</dc:creator>
<dc:creator>Kar-Ming Fung</dc:creator>
<dc:creator>Heather C Rice</dc:creator>
<dc:creator>Arnoud Sonnenberg</dc:creator>
<dc:creator>David Wu</dc:creator>
<dc:creator>Matthew S Walters</dc:creator>
<dc:creator>You-Yang Zhao</dc:creator>
<dc:creator>Tomoharu Kanie</dc:creator>
<dc:creator>Franklin A Hays</dc:creator>
<dc:creator>James F Papin</dc:creator>
<dc:creator>Dao Wen Wang</dc:creator>
<dc:creator>Xin A Zhang</dc:creator>
<dc:date>2024-04-01</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>CD151 Maintains Endolysosomal Protein Quality to Inhibit Vascular Inflammation</dc:title>
<dc:identifier>pmid:38557119</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.123.323190</dc:identifier>
</item>
<item>
<title>Modernizing Cardiovascular Medicine Board Certification: Leveraging Innovation and Strengthening Continuous Competency and Professional Growth</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38557064/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240402160831&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Apr 1. doi: 10.1161/CIRCULATIONAHA.124.069553. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38557064/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240402160831&v=2.18.0.post9+e462414">38557064</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.069553>10.1161/CIRCULATIONAHA.124.069553</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38557064</guid>
<pubDate>Mon, 01 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Joseph C Wu</dc:creator>
<dc:creator>B Hadley Wilson</dc:creator>
<dc:creator>James C Fang</dc:creator>
<dc:creator>Jodie L Hurwitz</dc:creator>
<dc:creator>George D Dangas</dc:creator>
<dc:date>2024-04-01</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Modernizing Cardiovascular Medicine Board Certification: Leveraging Innovation and Strengthening Continuous Competency and Professional Growth</dc:title>
<dc:identifier>pmid:38557064</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.069553</dc:identifier>
</item>
<item>
<title>LXRα Promotes Abdominal Aortic Aneurysm Formation Through UHRF1 Epigenetic Modification of miR-26b-3p</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38557060/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240402160831&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Our study reveals a pivotal role of the LXRα/UHRF1/miR-26b-3p axis in AAA and provides potential biomarkers and therapeutic targets for AAA.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Apr 1. doi: 10.1161/CIRCULATIONAHA.123.065202. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Abdominal aortic aneurysm (AAA) is a severe aortic disease without effective pharmacological approaches. The nuclear hormone receptor LXRα (liver X receptor α), encoded by the <i>NR1H3</i> gene, serves as a critical transcriptional mediator linked to several vascular pathologies, but its role in AAA remains elusive.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Through integrated analyses of human and murine AAA gene expression microarray data sets, we identified <i>NR1H3</i> as a candidate gene regulating AAA formation. To investigate the role of LXRα in AAA formation, we used global <i>Nr1h3</i>-knockout and vascular smooth muscle cell-specific <i>Nr1h3</i>-knockout mice in 2 AAA mouse models induced with angiotensin II (1000 ng·kg·min; 28 days) or calcium chloride (CaCl<sub>2</sub>; 0.5 mol/L; 42 days).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Upregulated LXRα was observed in the aortas of patients with AAA and in angiotensin II- or CaCl<sub>2</sub>-treated mice. Global or vascular smooth muscle cell-specific <i>Nr1h3</i> knockout inhibited AAA formation in 2 mouse models. Loss of LXRα function prevented extracellular matrix degeneration, inflammation, and vascular smooth muscle cell phenotypic switching. <i>Uhrf1</i>, an epigenetic master regulator, was identified as a direct target gene of LXRα by integrated analysis of transcriptome sequencing and chromatin immunoprecipitation sequencing. Susceptibility to AAA development was consistently enhanced by UHRF1 (ubiquitin-like containing PHD and RING finger domains 1) in both angiotensin II- and CaCl<sub>2</sub>-induced mouse models. We then determined the CpG methylation status and promoter accessibility of UHRF1-mediated genes using CUT&amp;Tag (cleavage under targets and tagmentation), RRBS (reduced representation bisulfite sequencing), and ATAC-seq (assay for transposase-accessible chromatin with sequencing) in vascular smooth muscle cells, which revealed that the recruitment of UHRF1 to the promoter of miR-26b led to DNA hypermethylation accompanied by relatively closed chromatin states, and caused downregulation of miR-26b expression in AAA. Regarding clinical significance, we found that underexpression of miR-26b-3p correlated with high risk in patients with AAA. Maintaining miR-26b-3p expression prevented AAA progression and alleviated the overall pathological process.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Our study reveals a pivotal role of the LXRα/UHRF1/miR-26b-3p axis in AAA and provides potential biomarkers and therapeutic targets for AAA.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38557060/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240402160831&v=2.18.0.post9+e462414">38557060</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065202>10.1161/CIRCULATIONAHA.123.065202</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38557060</guid>
<pubDate>Mon, 01 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Xiao Guo</dc:creator>
<dc:creator>Jianmei Zhong</dc:creator>
<dc:creator>Yichao Zhao</dc:creator>
<dc:creator>Yanan Fu</dc:creator>
<dc:creator>Ling-Yue Sun</dc:creator>
<dc:creator>Ancai Yuan</dc:creator>
<dc:creator>Junling Liu</dc:creator>
<dc:creator>Alex F Chen</dc:creator>
<dc:creator>Jun Pu</dc:creator>
<dc:date>2024-04-01</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>LXRα Promotes Abdominal Aortic Aneurysm Formation Through UHRF1 Epigenetic Modification of miR-26b-3p</dc:title>
<dc:identifier>pmid:38557060</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.065202</dc:identifier>
</item>
<item>
<title>BRCC3 Regulation of ALK2 in Vascular Smooth Muscle Cells: Implication in Pulmonary Hypertension</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38557054/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240402160831&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: These results suggest a pivotal role of BRCC3 in sustaining pulmonary vascular homeostasis by maintaining the integrity of the BMP signaling (ie, the ALK2-Smad1/5-PPARγ axis) while suppressing TGF-β signaling in PASMCs. Such rebalance of BMP/TGF-β pathways is translationally important for PAH alleviation.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Apr 1. doi: 10.1161/CIRCULATIONAHA.123.066430. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: An imbalance of antiproliferative BMP (bone morphogenetic protein) signaling and proliferative TGF-β (transforming growth factor-β) signaling is implicated in the development of pulmonary arterial hypertension (PAH). The posttranslational modification (eg, phosphorylation and ubiquitination) of TGF-β family receptors, including BMPR2 (bone morphogenetic protein type 2 receptor)/ALK2 (activin receptor-like kinase-2) and TGF-βR2/R1, and receptor-regulated (R) Smads significantly affects their activity and thus regulates the target cell fate. BRCC3 modifies the activity and stability of its substrate proteins through K63-dependent deubiquitination. By modulating the posttranslational modifications of the BMP/TGF-β-PPARγ pathway, BRCC3 may play a role in pulmonary vascular remodeling, hence the pathogenesis of PAH.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Bioinformatic analyses were used to explore the mechanism of BRCC3 deubiquitinates ALK2. Cultured pulmonary artery smooth muscle cells (PASMCs), mouse models, and specimens from patients with idiopathic PAH were used to investigate the rebalance between BMP and TGF-β signaling in regulating ALK2 phosphorylation and ubiquitination in the context of pulmonary hypertension.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: BRCC3 was significantly downregulated in PASMCs from patients with PAH and animals with experimental pulmonary hypertension. BRCC3, by de-ubiquitinating ALK2 at Lys-472 and Lys-475, activated receptor-regulated Smad1/5/9 (Smad1/5/9), which resulted in transcriptional activation of BMP-regulated PPARγ, p53, and Id1. Overexpression of BRCC3 also attenuated TGF-β signaling by downregulating TGF-β expression and inhibiting phosphorylation of Smad3. Experiments in vitro indicated that overexpression of BRCC3 or the de-ubiquitin-mimetic ALK2-K472/475R attenuated PASMC proliferation and migration and enhanced PASMC apoptosis. In SM22α-BRCC3-Tg mice, pulmonary hypertension was ameliorated because of activation of the ALK2-Smad1/5-PPARγ axis in PASMCs. In contrast, <i>Brcc3</i><sup>-/-</sup> mice showed increased susceptibility of experimental pulmonary hypertension because of inhibition of the ALK2-Smad1/5 signaling.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: These results suggest a pivotal role of BRCC3 in sustaining pulmonary vascular homeostasis by maintaining the integrity of the BMP signaling (ie, the ALK2-Smad1/5-PPARγ axis) while suppressing TGF-β signaling in PASMCs. Such rebalance of BMP/TGF-β pathways is translationally important for PAH alleviation.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38557054/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240402160831&v=2.18.0.post9+e462414">38557054</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.066430>10.1161/CIRCULATIONAHA.123.066430</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38557054</guid>
<pubDate>Mon, 01 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Hui Shen</dc:creator>
<dc:creator>Ya Gao</dc:creator>
<dc:creator>Dedong Ge</dc:creator>
<dc:creator>Meng Tan</dc:creator>
<dc:creator>Qing Yin</dc:creator>
<dc:creator>Tong-You Wade Wei</dc:creator>
<dc:creator>Fangzhou He</dc:creator>
<dc:creator>Tzong-Yi Lee</dc:creator>
<dc:creator>Zhongyan Li</dc:creator>
<dc:creator>Yuqin Chen</dc:creator>
<dc:creator>Qifeng Yang</dc:creator>
<dc:creator>Zhangyu Liu</dc:creator>
<dc:creator>Xinxin Li</dc:creator>
<dc:creator>Zixuan Chen</dc:creator>
<dc:creator>Yi Yang</dc:creator>
<dc:creator>Zhengang Zhang</dc:creator>
<dc:creator>Patricia A Thistlethwaite</dc:creator>
<dc:creator>Jian Wang</dc:creator>
<dc:creator>Atul Malhotra</dc:creator>
<dc:creator>Jason X-J Yuan</dc:creator>
<dc:creator>John Y-J Shyy</dc:creator>
<dc:creator>Kaizheng Gong</dc:creator>
<dc:date>2024-04-01</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>BRCC3 Regulation of ALK2 in Vascular Smooth Muscle Cells: Implication in Pulmonary Hypertension</dc:title>
<dc:identifier>pmid:38557054</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.066430</dc:identifier>
</item>
<item>
<title>Barcoding of episodic memories in the hippocampus of a food-caching bird</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38554707/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240402160831&amp;v=2.18.0.post9+e462414
      <description>The hippocampus is critical for episodic memory. Although hippocampal activity represents place and other behaviorally relevant variables, it is unclear how it encodes numerous memories of specific events in life. To study episodic coding, we leveraged the specialized behavior of chickadees-food-caching birds that form memories at well-defined moments in time whenever they cache food for subsequent retrieval. Our recordings during caching revealed very sparse, transient barcode-like patterns of...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Mar 22:S0092-8674(24)00235-6. doi: 10.1016/j.cell.2024.02.032. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">The hippocampus is critical for episodic memory. Although hippocampal activity represents place and other behaviorally relevant variables, it is unclear how it encodes numerous memories of specific events in life. To study episodic coding, we leveraged the specialized behavior of chickadees-food-caching birds that form memories at well-defined moments in time whenever they cache food for subsequent retrieval. Our recordings during caching revealed very sparse, transient barcode-like patterns of firing across hippocampal neurons. Each "barcode" uniquely represented a caching event and transiently reactivated during the retrieval of that specific cache. Barcodes co-occurred with the conventional activity of place cells but were uncorrelated even for nearby cache locations that had similar place codes. We propose that animals recall episodic memories by reactivating hippocampal barcodes. Similarly to computer hash codes, these patterns assign unique identifiers to different events and could be a mechanism for rapid formation and storage of many non-interfering memories.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38554707/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240402160831&v=2.18.0.post9+e462414">38554707</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.02.032>10.1016/j.cell.2024.02.032</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38554707</guid>
<pubDate>Sat, 30 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>Selmaan N Chettih</dc:creator>
<dc:creator>Emily L Mackevicius</dc:creator>
<dc:creator>Stephanie Hale</dc:creator>
<dc:creator>Dmitriy Aronov</dc:creator>
<dc:date>2024-03-30</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Barcoding of episodic memories in the hippocampus of a food-caching bird</dc:title>
<dc:identifier>pmid:38554707</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.02.032</dc:identifier>
</item>
<item>
<title>The SPATA5-SPATA5L1 ATPase complex directs replisome proteostasis to ensure genome integrity</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38554706/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240402160831&amp;v=2.18.0.post9+e462414
      <description>Ubiquitin-dependent unfolding of the CMG helicase by VCP/p97 is required to terminate DNA replication. Other replisome components are not processed in the same fashion, suggesting that additional mechanisms underlie replication protein turnover. Here, we identify replisome factor interactions with a protein complex composed of AAA+ ATPases SPATA5-SPATA5L1 together with heterodimeric partners C1orf109-CINP (55LCC). An integrative structural biology approach revealed a molecular architecture of...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Mar 22:S0092-8674(24)00250-2. doi: 10.1016/j.cell.2024.03.002. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Ubiquitin-dependent unfolding of the CMG helicase by VCP/p97 is required to terminate DNA replication. Other replisome components are not processed in the same fashion, suggesting that additional mechanisms underlie replication protein turnover. Here, we identify replisome factor interactions with a protein complex composed of AAA+ ATPases SPATA5-SPATA5L1 together with heterodimeric partners C1orf109-CINP (55LCC). An integrative structural biology approach revealed a molecular architecture of SPATA5-SPATA5L1 N-terminal domains interacting with C1orf109-CINP to form a funnel-like structure above a cylindrically shaped ATPase motor. Deficiency in the 55LCC complex elicited ubiquitin-independent proteotoxicity, replication stress, and severe chromosome instability. 55LCC showed ATPase activity that was specifically enhanced by replication fork DNA and was coupled to cysteine protease-dependent cleavage of replisome substrates in response to replication fork damage. These findings define 55LCC-mediated proteostasis as critical for replication fork progression and genome stability and provide a rationale for pathogenic variants seen in associated human neurodevelopmental disorders.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38554706/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240402160831&v=2.18.0.post9+e462414">38554706</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.03.002>10.1016/j.cell.2024.03.002</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38554706</guid>
<pubDate>Sat, 30 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>Vidhya Krishnamoorthy</dc:creator>
<dc:creator>Martina Foglizzo</dc:creator>
<dc:creator>Robert L Dilley</dc:creator>
<dc:creator>Angela Wu</dc:creator>
<dc:creator>Arindam Datta</dc:creator>
<dc:creator>Parul Dutta</dc:creator>
<dc:creator>Lisa J Campbell</dc:creator>
<dc:creator>Oksana Degtjarik</dc:creator>
<dc:creator>Laura J Musgrove</dc:creator>
<dc:creator>Antonio N Calabrese</dc:creator>
<dc:creator>Elton Zeqiraj</dc:creator>
<dc:creator>Roger A Greenberg</dc:creator>
<dc:date>2024-03-30</dc:date>
<dc:source>Cell</dc:source>
<dc:title>The SPATA5-SPATA5L1 ATPase complex directs replisome proteostasis to ensure genome integrity</dc:title>
<dc:identifier>pmid:38554706</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.03.002</dc:identifier>
</item>
<item>
<title>A streamlined pathway for transcatheter aortic valve implantation: the BENCHMARK study</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38554125/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240402160831&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Broad implementation of BENCHMARK practices contributes to improving efficiency of TAVI pathway reducing LoS and costs without compromising patient safety.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Mar 30:ehae147. doi: 10.1093/eurheartj/ehae147. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: There is significant potential to streamline the clinical pathway for patients undergoing transcatheter aortic valve implantation (TAVI). The purpose of this study was to evaluate the effect of implementing BENCHMARK best practices on the efficiency and safety of TAVI in 28 sites in 7 European countries.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: This was a study of patients with severe symptomatic aortic stenosis (AS) undergoing TAVI with balloon-expandable valves before and after implementation of BENCHMARK best practices. Principal objectives were to reduce hospital length of stay (LoS) and duration of intensive care stay. Secondary objective was to document patient safety.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Between January 2020 and March 2023, 897 patients were documented prior to and 1491 patients after the implementation of BENCHMARK practices. Patient characteristics were consistent with a known older TAVI population and only minor differences. Mean LoS was reduced from 7.7 ± 7.0 to 5.8 ± 5.6 days (median 6 vs. 4 days; P &lt; .001). Duration of intensive care was reduced from 1.8 to 1.3 days (median 1.1 vs. 0.9 days; P &lt; .001). Adoption of peri-procedure best practices led to increased use of local anaesthesia (96.1% vs. 84.3%; P &lt; .001) and decreased procedure (median 47 vs. 60 min; P &lt; .001) and intervention times (85 vs. 95 min; P &lt; .001). Thirty-day patient safety did not appear to be compromised with no differences in all-cause mortality (0.6% in both groups combined), stroke/transient ischaemic attack (1.4%), life-threatening bleeding (1.3%), stage 2/3 acute kidney injury (0.7%), and valve-related readmission (1.2%).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Broad implementation of BENCHMARK practices contributes to improving efficiency of TAVI pathway reducing LoS and costs without compromising patient safety.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38554125/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240402160831&v=2.18.0.post9+e462414">38554125</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae147>10.1093/eurheartj/ehae147</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38554125</guid>
<pubDate>Sat, 30 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>Derk Frank</dc:creator>
<dc:creator>Eric Durand</dc:creator>
<dc:creator>Sandra Lauck</dc:creator>
<dc:creator>Douglas F Muir</dc:creator>
<dc:creator>Mark Spence</dc:creator>
<dc:creator>Mariuca Vasa-Nicotera</dc:creator>
<dc:creator>David Wood</dc:creator>
<dc:creator>Francesco Saia</dc:creator>
<dc:creator>Cristóbal A Urbano-Carrillo</dc:creator>
<dc:creator>Damien Bouchayer</dc:creator>
<dc:creator>Vlad Anton Iliescu</dc:creator>
<dc:creator>Christophe Saint Etienne</dc:creator>
<dc:creator>Florence Leclercq</dc:creator>
<dc:creator>Vincent Auffret</dc:creator>
<dc:creator>Lluis Asmarats</dc:creator>
<dc:creator>Carlo Di Mario</dc:creator>
<dc:creator>Aurelie Veugeois</dc:creator>
<dc:creator>Jiri Maly</dc:creator>
<dc:creator>Andreas Schober</dc:creator>
<dc:creator>Luis Nombela-Franco</dc:creator>
<dc:creator>Nikos Werner</dc:creator>
<dc:creator>Joan Antoni Gómez-Hospital</dc:creator>
<dc:creator>Julia Mascherbauer</dc:creator>
<dc:creator>Giuseppe Musumeci</dc:creator>
<dc:creator>Nicolas Meneveau</dc:creator>
<dc:creator>Thibaud Meurice</dc:creator>
<dc:creator>Felix Mahfoud</dc:creator>
<dc:creator>Federico De Marco</dc:creator>
<dc:creator>Tim Seidler</dc:creator>
<dc:creator>Florian Leuschner</dc:creator>
<dc:creator>Patrick Joly</dc:creator>
<dc:creator>Jean-Philippe Collet</dc:creator>
<dc:creator>Ferdinand Vogt</dc:creator>
<dc:creator>Emilio Di Lorenzo</dc:creator>
<dc:creator>Elmar Kuhn</dc:creator>
<dc:creator>Vicente Peral Disdier</dc:creator>
<dc:creator>Violetta Hachaturyan</dc:creator>
<dc:creator>Claudia M Lüske</dc:creator>
<dc:creator>Radka Rakova</dc:creator>
<dc:creator>Wilbert Wesselink</dc:creator>
<dc:creator>Jana Kurucova</dc:creator>
<dc:creator>Peter Bramlage</dc:creator>
<dc:creator>Gemma McCalmont</dc:creator>
<dc:creator>BENCHMARK Investigator Group</dc:creator>
<dc:date>2024-03-30</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>A streamlined pathway for transcatheter aortic valve implantation: the BENCHMARK study</dc:title>
<dc:identifier>pmid:38554125</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae147</dc:identifier>
</item>
<item>
<title>Flexible scaffold-based cheminformatics approach for polypharmacological drug design</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38552625/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240402160831&amp;v=2.18.0.post9+e462414
      <description>Effective treatments for complex central nervous system (CNS) disorders require drugs with polypharmacology and multifunctionality, yet designing such drugs remains a challenge. Here, we present a flexible scaffold-based cheminformatics approach (FSCA) for the rational design of polypharmacological drugs. FSCA involves fitting a flexible scaffold to different receptors using different binding poses, as exemplified by IHCH-7179, which adopted a "bending-down" binding pose at 5-HT(2A)R to act as...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Mar 21:S0092-8674(24)00237-X. doi: 10.1016/j.cell.2024.02.034. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Effective treatments for complex central nervous system (CNS) disorders require drugs with polypharmacology and multifunctionality, yet designing such drugs remains a challenge. Here, we present a flexible scaffold-based cheminformatics approach (FSCA) for the rational design of polypharmacological drugs. FSCA involves fitting a flexible scaffold to different receptors using different binding poses, as exemplified by IHCH-7179, which adopted a "bending-down" binding pose at 5-HT<sub>2A</sub>R to act as an antagonist and a "stretching-up" binding pose at 5-HT<sub>1A</sub>R to function as an agonist. IHCH-7179 demonstrated promising results in alleviating cognitive deficits and psychoactive symptoms in mice by blocking 5-HT<sub>2A</sub>R for psychoactive symptoms and activating 5-HT<sub>1A</sub>R to alleviate cognitive deficits. By analyzing aminergic receptor structures, we identified two featured motifs, the "agonist filter" and "conformation shaper," which determine ligand binding pose and predict activity at aminergic receptors. With these motifs, FSCA can be applied to the design of polypharmacological ligands at other receptors.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38552625/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240402160831&v=2.18.0.post9+e462414">38552625</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.02.034>10.1016/j.cell.2024.02.034</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38552625</guid>
<pubDate>Fri, 29 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>Zhangcheng Chen</dc:creator>
<dc:creator>Jing Yu</dc:creator>
<dc:creator>Huan Wang</dc:creator>
<dc:creator>Peiyu Xu</dc:creator>
<dc:creator>Luyu Fan</dc:creator>
<dc:creator>Fengxiu Sun</dc:creator>
<dc:creator>Sijie Huang</dc:creator>
<dc:creator>Pei Zhang</dc:creator>
<dc:creator>He Huang</dc:creator>
<dc:creator>Shuo Gu</dc:creator>
<dc:creator>Bowen Zhang</dc:creator>
<dc:creator>Yue Zhou</dc:creator>
<dc:creator>Xiaobo Wan</dc:creator>
<dc:creator>Gang Pei</dc:creator>
<dc:creator>H Eric Xu</dc:creator>
<dc:creator>Jianjun Cheng</dc:creator>
<dc:creator>Sheng Wang</dc:creator>
<dc:date>2024-03-29</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Flexible scaffold-based cheminformatics approach for polypharmacological drug design</dc:title>
<dc:identifier>pmid:38552625</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.02.034</dc:identifier>
</item>





























</channel>
</rss>